Early intervention in the treatment of rheumatoid arthritis: Focus on tocilizumab

Therapeutics and Clinical Risk Management

Volumn 9, Issue 1, 2013, Pages 403-408

  Yilmaz, Sedat ^a   Simsek, Ismail ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Early intervention; Rheumatoid arthritis; Tocilizumab

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; INTERLEUKIN 6; METHOTREXATE; PLACEBO; TOCILIZUMAB;

DISEASE ACTIVITY SCORE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; REVIEW; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS DISEASE ACTIVITY INDEX; TREATMENT RESPONSE;

EID: 84889790196     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S35784     Document Type: Review

References (36)

1. Gabriel SE, Michaud K. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Res Ther. 2009;11(3):229.
2. Pincus T, Kavanaugh A, Sokka T. Benefit/risk of therapies for rheumatoid arthritis: underestimation of the "side effects" or risks of RA leads to underestimation of the benefit/risk of therapies. Clin Exp Rheumatol. 2004;22(5) Suppl 35:2-11.
3. Nam JL, Winthrop KL, van Vollenhoven RF, etal. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis. 2010;69(6):976-986
4. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum. 2000;43:22-29.
5. Emery P, Breedveld FC, Hall S, etal. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet. 2008;372:375-382.
6. Breedveld FC, Weisman MH, Kavanaugh AF, etal. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37.
7. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, etal. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum. 2005;52:3381-3390.
8. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. Clin Rheumatol. 2009;28(4):413-419.
9. Gómez-Reino J. Biologic monotherapy as initial treatment in patients with early rheumatoid arthritis. Rheumatology (Oxford). 2012;51 Suppl 5:v31-v37.
10. Keystone EC, Haraoui B, Bykerk VP. Role of infliximab in the treatment of early rheumatoid arthritis. Clin Exp Rheumatol. 2003; 21(5) Suppl 31:200-202.
11. Yazici Y, McMorris BJ, Darkow T, Rosenblatt LC. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2009;27:907-913.
12. Aletaha D, Eberl G, Nell VP, Machold KP, Smolen JS. Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis. 2004;63(10):1269-1275.
13. Klein B, Wijdenes J, Zhang XG, Jourdan M, Boiron JM, Brochier J. Murine anti-interleukin-6monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991;78:1198-1204.
14. Sato K, Tsuchiya M, Saldanha J, etal. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 1993;53(4):851-856.
15. Beck JT, Hsu SM, Wijdenes J, etal. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330:602-605.
16. Sack U, Kinne RW, Marx T, Heppt P, Bender S, Emmrich F. Interleukin-6in synovial fluid is closely associated with chronic synovitis in rheumatoid arthritis. Rheumatol Int. 1993;13(2):45-51.
17. Pharmaceuticals and Medical Devices Agency [homepage on the internet]. Tokyo, Japan. Available from http://www.pmda.go.jp/english/service/pdf/drugs/actemra_apr2008_e.pdf. Accessed September 30, 2013.
18. European Medicines Agency [homepage on the internet]. London. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_asses sment_report/human/000955/WC500054888.pdf/. Accessed September 30, 2013.
19. U.S. Food and Drug Administration [homepage on the internet]. USA. Available from http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/125276s000TOC.cfm . Accessed September 30, 2013.
20. Nishimoto N, Hashimoto J, Miyasaka N, etal. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162-1167.
21. Maini RN, Taylor PC, Szechinski J, etal. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829.
22. Jones G, Sebba A, Gu J, etal. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69:88-96.
23. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol. 2010;6(2):189-195.
24. Burmester G, Rigby W, Vollenhoven RV, etal. Tocilizumab in combination and monotherapy versus methotrexate in methotrexate-naive patients with early rheumatoid arthritis: clinical and radiographic outcomes from a randomised, placebo-controlled trial. Ann Rheum Dis. 2013;72(Suppl 3):63.
25. Durez P, Depresseux G, Toukap AN, etal. Rate of remission by tocilizumab or methotrexate induction therapy in early active rheumatoid arthritis: results of the TOMERA trial. Ann Rheum Dis. 2013; 72(Suppl 3):623.
26. Smolen JS, Beaulieu A, Rubbert-Roth A, etal. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet. 2008:22;371(9617):987-997.
27. Genovese MC, McKay JD, Nasonov EL, etal. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968-2980.
28. Kojima T, Kaneko A, Hirano Y, etal. Early aggressive intervention with tocilizumab for rheumatoid arthritis increases remission rate defined using a Boolean approach in clinical practice. Mod Rheumatol. 2012;22(3):370-375.
29. Yabe Y, Kojima T, Kaneko A, Asai N, Kobayakawa T, Ishiguro N. A review of tocilizumab treatment in 122 rheumatoid arthritis patients included in the Tsurumai Biologics Communication Registry (TBCR) Study. Mod Rheumatol. 2013;23(2):245-253.
30. Felson DT, Smolen JS, Wells G, etal; American College of Rheumatology; European League Against Rheumatism. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011;63:573-586.
31. Houssiau FA, Devogelaer JP, van Damme J, de Deuxchaisnes CN, Van Snick J. Interleukin-6in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 1988;31:784-788.
32. Nakahara H, Song J, Sugimoto M, etal. Anti-interleukin-6 receptor antibody therapy reduces vascular endothelial growth factor production in rheumatoid arthritis. Arthritis Rheum. 2003;48:1521-1529.
33. Kayakabe K, Kuroiwa T, Sakurai N, etal. Interleukin-6 promotes destabilized angiogenesis by modulating angiopoietin expression in rheumatoid arthritis. Rheumatology (Oxford). 2012;51(9):1571-1579.
34. Firestein GS. Starving the synovium: angiogenesis and inflammation in rheumatoid arthritis. J Clin Invest. 1999;103:3-4.
35. Palmqvist P, Persson E, Conaway HH, Lerner UH. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol. 2002;169(6):3353-3362.
36. Karsdal MA, Schett G, Emery P, etal. IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522). Semin Arthritis Rheum. 2012;42(2):131-139.